Wall Street analysts forecast that Heron Therapeutics Inc (NASDAQ:HRTX) will report sales of $4.53 million for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Heron Therapeutics’ earnings, with estimates ranging from $4.36 million to $4.7 million. The company is scheduled to report its next earnings report on Monday, August 14th.

According to Zacks, analysts expect that Heron Therapeutics will report full-year sales of $4.53 million for the current year, with estimates ranging from $21.02 million to $22.9 million. For the next year, analysts expect that the company will post sales of $83.9 million per share. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Wednesday, May 10th. The biotechnology company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.94) by $0.06. The business had revenue of $3.63 million for the quarter, compared to the consensus estimate of $1.96 million.

Several brokerages have commented on HRTX. Cowen and Company reiterated a “buy” rating and issued a $40.00 price target on shares of Heron Therapeutics in a research note on Friday. Noble Financial reiterated a “buy” rating on shares of Heron Therapeutics in a research note on Friday, May 12th. Cantor Fitzgerald reiterated a “buy” rating and issued a $31.00 price target (up from $30.00) on shares of Heron Therapeutics in a research note on Thursday, May 11th. Zacks Investment Research lowered shares of Heron Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, May 9th. Finally, Jefferies Group LLC restated a “buy” rating and set a $29.00 target price on shares of Heron Therapeutics in a research report on Monday, April 10th. One analyst has rated the stock with a sell rating and ten have issued a buy rating to the stock. Heron Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $34.50.

Shares of Heron Therapeutics (NASDAQ:HRTX) opened at 13.95 on Friday. The firm’s 50-day moving average is $14.78 and its 200 day moving average is $14.57. Heron Therapeutics has a 52-week low of $12.21 and a 52-week high of $24.00.

In other news, VP Kimberly Manhard sold 21,542 shares of the firm’s stock in a transaction that occurred on Monday, April 24th. The shares were sold at an average price of $15.33, for a total transaction of $330,238.86. Following the transaction, the vice president now directly owns 5,250 shares in the company, valued at $80,482.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 20.31% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. Tang Capital Management LLC raised its position in Heron Therapeutics by 39.7% in the first quarter. Tang Capital Management LLC now owns 8,654,914 shares of the biotechnology company’s stock worth $129,824,000 after buying an additional 2,457,716 shares during the period. FMR LLC raised its position in Heron Therapeutics by 36.7% in the first quarter. FMR LLC now owns 8,030,880 shares of the biotechnology company’s stock worth $120,464,000 after buying an additional 2,158,041 shares during the period. Janus Capital Management LLC raised its position in Heron Therapeutics by 20.2% in the first quarter. Janus Capital Management LLC now owns 5,501,755 shares of the biotechnology company’s stock worth $82,524,000 after buying an additional 925,948 shares during the period. Broadfin Capital LLC raised its position in Heron Therapeutics by 26.9% in the first quarter. Broadfin Capital LLC now owns 4,947,403 shares of the biotechnology company’s stock worth $74,211,000 after buying an additional 1,047,816 shares during the period. Finally, Vanguard Group Inc. raised its position in Heron Therapeutics by 40.2% in the first quarter. Vanguard Group Inc. now owns 1,875,103 shares of the biotechnology company’s stock worth $28,127,000 after buying an additional 537,563 shares during the period.

TRADEMARK VIOLATION NOTICE: “$4.53 Million in Sales Expected for Heron Therapeutics Inc (HRTX) This Quarter” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/05/28/4-53-million-in-sales-expected-for-heron-therapeutics-inc-hrtx-this-quarter.html.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

12 Month Chart for NASDAQ:HRTX

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Heron Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.